Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
Become a Member | Sign in
Home>News>This Article

LGC Acquires Quotient’s Bioanalytical Business

Published: Friday, January 04, 2013
Last Updated: Friday, January 04, 2013
Bookmark and Share
Acquisition will enable LGC to provide an enhanced range of products and services to the pharmaceutical sector.

LGC and Quotient Bioresearch has announced that they have reached agreement on the sale by Quotient of its Bioanalytical Sciences division to LGC.

Quotient Bioanalytical Sciences is a leading provider of bioanalytical services across the fields of small molecules, biomarkers, biopharmaceuticals and microbiological testing to customers in the pharmaceutical and biotechnology sectors. It is based at Fordham, Cambridgeshire.

The acquisition, which will form part of LGC’s Health Sciences division, will enable LGC to provide an enhanced range of products and services to the pharmaceutical sector including bioanalysis, materials science and reference materials amongst others.

Under the terms of the transaction, Quotient and LGC have committed to collaborate as preferred partners on the provision of Bioanalytical Sciences.

This will enable clients to continue to benefit from the early development services offered by the Quotient group including clinical trials, metabolism and radiolabelling.

The Bioanalytical Sciences business will continue to trade using the “Quotient” name under its new ownership for the time being.

The transaction follows the sale two years ago by Quotient to LGC of HFL Sport Science, which is also based at the Fordham site.

Jeremy Cook, Managing Director of LGC’s Health Sciences said, “We’re delighted to have acquired Quotient Bioanalytical Sciences, a high quality business which is complementary to our existing activities. We continue to develop our range of first-rate services in the pharmaceutical, biotechnology and agrochemical sectors by offering our customers a unique mix of technical experience, leading edge facilities and knowledgeable people.”

Dr Steve Pleasance, Managing Director of Quotient Bioanalytical Sciences said “LGC’s focus on complex analytical chemistry, high quality science and service delivery make them a natural home for our business. Both our organizations have reputations built upon quality and innovation and LGC’s global presence will help support the continued growth of services to our customers.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Quotient Clinical CEO Mark Egerton a Winner at UK EY Entrepreneur of the Year 2015 Awards
Quotient Clinical has announced that CEO Mark Egerton has received an EY Entrepreneur of the Year® 2015 UK Award.
Thursday, October 08, 2015
Quotient Clinical Reports Another Successful Year of Record Growth
Operating capacity set to more than double in response to rising demand.
Wednesday, May 13, 2015
Quotient Clinical and Bend Research Announce Collaboration to Accelerate Advancement of new Medicines
Complementary capabilities will cut development time and expand options for a wide range of drugs.
Thursday, November 11, 2010
Quotient Bioresearch Announce Collaboration with Clinical Reference Laboratory
The Collaborators will jointly offer clinical laboratory and other specialist testing services to support the two Group’s clients world wide.
Tuesday, August 25, 2009
Quotient Clinical Receives MHRA Supplementary Accreditation
Accreditation qualifies Quotient Clinical to perform FIH studies for low molecular weight chemical entities and biologics.
Friday, July 10, 2009
Quotient Bioresearch Acquires Edinburgh Clinical Research Facility from Charles River Laboratories
The Charles River facility will combine with Pharmaceutical Profiles to form a new strategic business unit, Quotient Clinical.
Thursday, May 21, 2009
Scientific News
Lucentis Effective for Proliferative Diabetic Retinopathy
NIH-funded clinical trial marks first major advance in therapy in 40 years.
Blocking the Transmission Of Malaria Parasites
Vaccine candidate administered for the first time in humans in a phase I clinical trial led by Oxford University’s Jenner Institute, with partners Imaxio and GSK.
First Therapy Appearing to Reverse Decline in Parkinson’s
An FDA-approved drug for leukemia improved cognition, motor skills and non-motor function in patients with Parkinson’s disease and Lewy body dementia in a small clinical trial, say researchers at Georgetown University Medical Center (GUMC).
Gene Therapy Staves Off Blindness from Retinitis Pigmentosa in Canine Model
NIH-funded study suggests therapeutic window may extend to later-stage disease.
Treatment for Rare Bleeding Disorder is Effective
Researchers in Manchester have demonstrated for the first time the relative safety and effectiveness of treatment, eltrombopag, in children with persistent or chronic immune thrombocytopenia (ITP), as part of an international duo of studies.
HIV Vaccine Human Trials Begin
Baltimore-based Institute has begun enrolling volunteers for initial phase 1 clinical trials.
New Therapy Reduces Symptoms of Inherited Enzyme Deficiency
A phase three clinical trial of a new enzyme replacement medication, sebelipase alfa, showed a reduction in multiple disease-related symptoms in children and adults with lysosomal acid lipase deficiency, an inherited enzyme deficiency that can result in scarring of the liver and high cholesterol.
Fixing Holes in the Heart Without Invasive Surgery
UV-light enabled catheter is a medical device which represents a major shift in how cardiac defects are repaired.
Atriva Therapeutics GmbH Develops Innovative Flu Drug
Highly effective against seasonal and pandemic influenza.
Study Removes Cancer Doubt for Multiple Sclerosis Drug
Researchers from Queen Mary University of London are calling on the medical community to reconsider developing a known drug to treat people with relapsing Multiple sclerosis after new evidence shows it does not increase the risk of cancer as previously thought.
Scroll Up
Scroll Down

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos